104
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Evaluation of Liver Metabolism Biomarkers in Metabolic Associated Fatty Liver Disease According to Obesity Phenotype

, , , , , & show all
Pages 140-147 | Received 20 Jul 2021, Accepted 11 Nov 2021, Published online: 15 Feb 2022

References

  • Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81. doi:10.1016/S0140-6736(14)60460-8.
  • NCD, Risk Factor C, (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–96. doi:10.1016/S0140-6736(16)30054-X.
  • Cabral JAV, Souza G. P d, Nascimento J. d A, Simoneti LF, Marchese C, Sales-Peres S. H d C. Sales-Peres SH. Impact of vitamin D and calcium deficiency in the bones of patients undergoing bariatric surgery: a systematic review. ABCD, Arq Bras Cir Dig. 2016;29(1 Suppl):120–3. doi:10.1590/0102-6720201600s10029.
  • Chen Y-Y, Fang W-H, Wang C-C, Kao T-W, Chang Y-W, Wu C-J, Zhou Y-C, Sun Y-S, Chen W-L. Body fat has stronger associations with bone mass density than body mass index in metabolically healthy obesity. PLoS One. 2018;13(11):e0206812. doi:10.1371/journal.pone.0206812.
  • National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
  • Eslam M, Sanyal AJ, George J. Are non-alcoholic fatty liver disease and alcoholic fatty liver disease more than just semantics? Gastroenterology. 2019;157(3):590–3.
  • Pujia A, Gazzaruso C, Ferro Y, Mazza E, Maurotti S, Russo C, Lazzaro V, Romeo S, Montalcini T. Individuals with metabolically healthy overweight/obesity have higher fat utilization than metabolically unhealthy individuals. Nutrients. 2016;8(1):2. doi:10.3390/nu8010002.
  • Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65(8):1017–25. doi:10.1016/j.metabol.2016.01.012. doi:10.1016/j.metabol.2016.01.012.
  • Okur G, Karacaer Z. The prevalence of non-alcoholic fatty liver disease in healthy young persons. Northern Clin Istanbul. 2016;3(2):111–7.
  • Huh JH, Kim KJ, Kim SU, Han SH, Han K-H, Cha B-S, Chung CH, Lee B-W. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism. 2017;66:23–31. doi:10.1016/j.metabol.2016.10.003.
  • Brea Á, Pinto X, Ascaso JF. Enfermedaddelhígadograso no alcohólico, asociaciónconlaenfermedad cardiovascular y tratamento (I). Enfermedaddelhígadograso no alcohólico y suasociaciónconlaenfermedad cardiovascular. Invest Arterioscler. 2017;29(3):141–8.
  • Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl. 1):S11–S6.
  • National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, 2002. Available from: http://www2.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm. Accessed November 20, 2017.
  • Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39. doi:10.1161/01.CIR.0000133317.49796.0E.
  • World Health Organization (WHO) Obesity: preventing and managing the global epidemic. Geneva: WHO; 2004.
  • Lohman T, Caballero B, Davis S. Pathways: a school-based program for the primary prevention of obesity in American Indian children. J Nutr. 1998;9(9):535–43.
  • Pratt DS, Kaplan MM. Avaliação da funçãohepática [Liverfunctionassessment]. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson LR, editors. Harrison medicina interna [Harrison internal medicine]. 15th ed. Rio de Janeiro: McGraw Hill; 2002. p. 1813–6.
  • Sociedade Brasileira de Cardiologia (SBC). VII Diretriz Brasileira de Hipertensão Arterial. 2016. Available from: <http://publicacoes.cardiol.br/2014/diretrizes/2016/05_HIPERTENSAO_ARTERIAL.pdf. >. Accessed February 2, 2016.
  • American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Suppl. 1):S13–S28.
  • Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. doi:10.1093/clinchem/18.6.499.
  • Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP, Grimer RJ. Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localized osteosarcoma. Eur J Cancer. 2005;41(18):2846–52. doi:10.1016/j.ejca.2005.07.024.
  • Bahia CA, Guimarães RM, Asmus CIRF. Alterações nos marcadores hepáticos decorrentes da exposição ambiental a organoclorados no Brasil. Cad Saúde Colet. 2014;22 (2):133–41. doi:10.1590/1414-462X201400020005.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9. doi:10.1007/BF00280883.
  • Durward CM, Hartman TJ, Nickols-Richardson SM. All-cause mortality risk of metabolically healthy obese individuals in NHANES III. J Obes. 2012;2012:1–12. doi:10.1155/2012/460321.
  • Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S–6S. doi:10.1093/ajcn/87.4.1080S.
  • Hanwell HEC, Vieth R, Cole DEC, Scillitani A, Modoni S, Frusciante V, Ritrovato G, Chiodini I, Minisola S, Carnevale V, et al. Sun exposure questionnaire predicts circulating 25-hydroxyvitamin D concentrations in Caucasian hospital workers in southern Italy. J Steroid Biochem Mol Biol. 2010;121(1-2):334–7. doi:10.1016/j.jsbmb.2010.03.023.
  • World Health Organization (WHO). The World Health Report, Fighting disease, fostering development. 1996. Availablefrom: www.who.int/whr/1996/en/. Accessed June 6, 2016.
  • Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467–74. doi:10.1111/j.1572-0241.1999.01377.x.
  • IBM Corp. Released 2012. IBM SPSS statistics for windows, Version 21.0. Armonk (NY): IBM Corp.
  • Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103(1):22–7. doi:10.1097/TP.0000000000002484.
  • Xu L, Jiang CQ, Schooling CM, Zhang WS, Cheng KK, Lam TH. Liver enzymes as mediators of association between obesity and diabetes: the Guangzhou Biobank Cohort Study. Ann Epidemiol. 2017;27(3):204–7. doi:10.1016/j.annepidem.2016.11.002.
  • Ali AT, Penny CB, Paiker JE, Psaras G, Ikram F, Crowther NJ. The relationship between alkaline phosphatase activity and intracellular lipid accumulation in murine 3T3-L1 cells and human preadipocytes. Anal Biochem. 2006;354(2):247–54. doi:10.1016/j.ab.2006.04.028.
  • Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F. Perticone, association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers. Nutr Metab Cardiovasc Dis. 2013;23(12):1182–7. doi:10.1016/j.numecd.2013.01.006.
  • Patel PS, Buras ED, Balasubramanyam A. The role of the immune system in obesity and insulin resistance. J Obes. 2013;2013:1–9.
  • Ong T, Sahota O, Tan W, Marshall L. A United Kingdom perspective on the relationship between body mass index (BMI) and bone health: a cross sectional analysis of data from the Nottingham Fracture Liaison Service. Bone. 2014;59:207–10. doi:10.1016/j.bone.2013.11.024.
  • Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758–69. doi:10.7326/0003-4819-159-11-201312030-00008.
  • Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019;62(4):558–66. doi:10.1007/s00125-018-4787-8.
  • März W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A, Parhofer KG, von Eckardstein A, Landmesser U, Laufs U. HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol. 2017;106(9):663–75. doi:10.1007/s00392-017-1106-1.
  • Gariani K, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. Endocr Connect. 2021;10(2):R52–R65. doi:10.1530/EC-20-0490.
  • Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207–15. doi:10.1159/000471488.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.